A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL
Status:
Active, not recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
This research study is evaluating a combination of drugs called Ofatumumab and Idelalisib as
a possible treatment for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Leukemia
(SLL).
The main purpose of this study is to examine the combination of the two drugs, Ofatumumab and
Idelalisib, in participants who have been diagnosed with CLL/SLL and have not previously
received treatment but do require treatment. The investigators hope to observe how
participants' disease will be impacted by this treatment and whether they will benefit more
from combining these drugs together rather than taking them separately. Both of these drugs
have been used in treatment for CLL / SLL and information from those research studies
suggests that these drugs may help patients with CLL/SLL.
Ofatumumab is an antibody engineered in the lab against CD20, a protein on the surface of CLL
cells, which is expressed in CLL. An antibody is a molecule your body creates to identify
foreign substances so that it can destroy them. Ofatumumab has been FDA approved for
treatment of CLL/SLL that has relapsed or progressed on other therapies. Idelalisib is a drug
that blocks one of the signals inside the cells that cause this type of cancer to grow and
survive. The investigators hope that combining Ofatumumab with Idelalisib will stop the
growth of disease.
In this research study, the investigators are evaluating the side effects of combining these
two drugs, gathering information on the CLL/SLL disease process and how the study affects the
patient's cells, as well as assessing the outcome of the disease. This combination of drugs
has been previously tested, and appeared to be well tolerated.